Biotech Values

[mcbio]

Well, there's not much there to sink our teeth into is there?

Yeah, not too much and clearly very early but just seeing if maybe there's a hint of hope here. I just tend to think the market doesn't assign much value to PGNX for this drug (think most of the value is tied to Relistor) and this could have the chance to be a value-driver down the road for them if results pan out.

Off-hand I would not put much weight into PSA. I think you're of the same inclination.

Thanks for confirmation of my thoughts on that.

As for the CTCs, I looked at the abstract and couldn't really see how they measure them. What is the marker they use to identify them? Do they sort them by FACS?

One of the things to be careful with these various "circulating" cells is that they're often very low in number, and the reproducibility of the measurement is therefore rather poor. I see a lot of this type of "circulating progenitor cell" type data around my area, and the numbers of cells identifiable is usually very low and, due to that, poorly reproducible. Without knowing what the magnitudes of those CTCs are, I wouldn't be too reliant on those data.

Thanks for the caveat here on how CTCs are measured. I have no idea how PGNX is measuring them here and whether they are doing so in a normal or controversial manner. Will continue to keep an eye on this PSMA ADC though and see what more concrete data brings down the road. Hopefully this is something that could draw partnering interest as well, presumably only with more concrete data. Though I may take some chips off the table here, I'm going to continue to hold part of my PGNX position in part because of this drug.